When Great Obesity Study Results May Not Be Enough (OREX)
Orexigen Therapeutics, Inc. (NASDAQ: OREX) is moving in after-hours trading. The company has just announced that its first of four Phase III trials of its lead investigational product Contrave met its co-primary and key secondary endpoints. Be advised that there are questions about how this really fits in with the “targets” and the stock is indicated lower after the results.
This showed a significant reduction in body weight, improvements in markers of cardiovascular risk and reductions in selected food craving measures. If you can believe it, the result was a loss of about 20 to 25 pounds. This was with an exercise regimen and did include counselling, but generally speaking many who need to lose that much do better with ongoing reviews.
Here is the full release from the company.
Jon C. Ogg
January 8, 2009